
A CASE OF MODY 2 - ASSOCIATED HYPERGLYCEMIA
DIAGNOSED AS GESTATIONAL DIABETES Chakarova N.1, Balabanski L.2,3, Dimova R.1, Tsarkova P.1, Tankova T.1 *Corresponding Author: Nevena Chakarova, MD, PhD, Department of Endocrinology Medical University
Sofia, 1431 Sofia, 2 Zdrave Str., e-mail: veni_chakarova@abv.bg, ORCID ID 0000-0001-7606-5060 page: 4
|
CASE PRESENTATION
A 43-year-old woman was referred to the department
of Diabetology for assessment of glucose tolerance. She had
a history of gestational diabetes during her first pregnancy
at the age of 26 with fasting glucose concentrations of 7
to 8 mmol/l. She did not receive insulin therapy during
pregnancy and her glucose tolerance was not reassessed
after delivery nor during her second pregnancy. Both babies
weighted below 4 kg at birth – 3650 g and 3000 g, respectively,
but the first delivery was 2 weeks preterm. In the
following years her fasting glucose was constantly within
the range of 6.5 to 8.2 mmol/l and metformin therapy was
initiated. The patient had concomitant autoimmune thyroiditis
and beta thalassemia. The family history was abundant
- her father had elevated fasting glucose values around 8
mmol/l though he was never treated for hyperglycemia, her
mother had Grave’s disease and vitiligo, one of the patient’s sons, a first cousin, and a nephew all had beta thalassemia.
Physical examination revealed no abnormalities, the patient
had a BMI of 19.5 kg/m2, waist circumference of 71 cm
and blood pressure of 120/70 mmHg.
Clinical investigation
- Assessment of glucose tolerance and insulin resistance
- oral glucose tolerance test ( OGTT) was performed
after discontinuation of metformin and revealed a
state of prediabetes - impaired fasting glucose. Fasting
insulin was low normal and calculated HOMA IR
was within range. (Table 1) HbA1c was 5.2% in the
setting of hemoglobin concentration of 126 G/l.
- Assessment of immunologic markers - islet cell
antibodies - anti-GAD 65-Ab, anti-IA 2-Ab and
anti-ZnT8-Ab, were negative.
- Assessment of insulin secretion - intravenous glucose
tolerance test (IVGTT) demonstrated preserved
endogenous insulin secretion. (Table 2)
- Assessment of glycemic control - continuous glucose
monitoring (CGM) (FreeStyle Libre) showed
good glycemic control and no need of pharmacologic
therapy at this stage. (Figure 1)
- Other - serum lipids and TSH were within normal
range.
Genetic testing
- NGS sequencing
Based on clinical suspicion of a specific monogenic
form of diabetes running in her family the patient was
referred for genetic testing. Genomic DNA was extracted
from a blood sample taken after informed consent was
signed. A custom panel was used for library preparation
that included the exons and exon-intron boundaries of
99 genes associated with different syndromic and nonsyndromic
causes of monogenic diabetes. All 14 genes implicated
in the different subtypes of MODY were included
in the gene panel. Next-generation sequencing (NGS) was
performed on an Illumina MiSeq platform.
- NGS data analysis and variant classification
MiSeq reporter software was used for standard bioinformatic
analysis. The generated VCF file was annotated
using wANNOVAR software [6]. After common polymorphisms
were filtered out, all remaining rare variants
were classified according to the ACMG guidelines [7].
The patient was found to be a carrier of a heterozygous
pathogenic variant in GCK (c.184G>A).
|
|
|
|



 |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|